In an NHS e-mail with a wide distribution list, I was invited to this marketing event.
Though it is titled “Current updates in treatment for schizophrenia” the following programme demonstrates that this is a marketing event by Sunovion to promote Latuda:
I have written before about the determined marketing of Latuda to UK psychiatrists as supported by the British Association of Psychopharmacology.
One of the paid speakers in the above meeting, Professor Oliver Howes, is on the Royal College of Psychiatrists Psychopharmacology Committee.
Professor Peter Haddad continues to be involved in a wide range of sponsored education.
SUNOVION were investigated by the PMCPA in 2016 in relation to the marketing of Latuda to health professionals and were found to have breached Clauses 8.2 and 9.1